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Abstract  Article Information 
The objective of the current study was to develop and validate a simple, accurate, precise 
and selective stability-indicating gradient reverse phase high performance liquid 
chromatographic method for simultaneous estimation of Ofloxacin and Cefixime in 
pharmaceutical formulation in presence of degradation products. The chromatographic 
separation of Ofloxacin and Cefixime was achieved on Shimadzu LC-20AT  series HPLC  
having  C18-ODS  bonded column (250 ×4.6 mm, 40 °C, 10 μL) using UV/Visible detector at 
276 nm.  The optimized mobile phase was consisted of a methanol: phosphate buffer 
(50:50) at a flow rate of 1.0 ml/m.  The retention times were 4.799 and 1.602 m for Ofloxacin 
and Cefixime respectively.  The proposed method provided linear responses within the 
concentration ranges 5-25 µg/ml for Ofloxacin and Cefixime both. The limit of detection 
(LOD) and limit of quantification (LOQ) values were found to be 0.0259, 0.078 µg/ml and 
0.0206, 0.062 µg/ml for Ofloxacin and Cefixime F respectively. The developed method was 
validated as per ICH guidelines with respect to specificity, linearity, accuracy, precision, 
robustness and ruggedness. The studies data revealed that developed method was 
convenient, fairly reliable, sensitive, less expensive and reproducible.   
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INTRODUCTION 
Ofloxacin (OFL) are wide spectrum quinolones and 
Cefixime (CEF) is a third-generation cephalosporin with a 
wider spectrum of activity against gram-positive and 
gram-negative bacteria and anaerobics (Ozyüncü et al., 
2010). OFL chemically is a fluorinated carboxy quinolone, 
is a racemate, (±)‐ 9‐fluro‐2, 3‐dihydro‐3‐methyl‐10‐ 
4‐methyl‐1‐piperazinyl)‐7‐oxo‐7H‐pyrido[1,2,3‐de]‐1,4‐ben
zoxazine‐ 6‐carboxylic acid (Figure 1A) that is active 
against both Gram-positive and Gram-negative bacteria. It 
is mainly used for the treatment of urinary tract infection 
and sexually transmitted diseases and also are good 
candidates for the development of more powerful 
treatment of leprosy (Chopra et al., 2001 and Veziris et 
al., 2013). OFL is a fluoroquinolone antibiotic with activity 
against various micro-organisms causing Acute 
exacerbation of chronic obstructive pulmonary disease 
(AECOPD) (Yoon etal., 2013). It inhibits DNA gyrase, a 
type II topoisomerase, and topoisomerase IV. CEF is 
chemically known as (6R, 7R)-7-{[2-(2-amino-1,3-thiazol-
4-yl)2(carboxymethoxyimino) acetyl]amino}-3-ethenyl-8-
oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid 
(Figure 1B) (Ali Ahmed et al., 2013). CEF is the extended-
spectrum cephalosporins, are currently the recommended 
first-line antimicrobials in most countries worldwide, can 
be used for the treatment of gonorrhea as an empirical 
first-line therapy (Sethi et al., 2013 and Olsen et al., 
2013). Synthesis of cell wall inhibit by the bactericidal 
action of cephalosporin, which inhibits the final 
transpeptidation step of the peptidoglycan synthesis in the 
bacterial cell wall, thus inhibiting biosynthesis of cell wall 
assembly by arresting, resulting in bacterial cell death. 
 
Elbashir et al., 2012, Khan et al., 2011, Nemutlu et al., 
2009, Pulgarín et al., 2013, Hubicka et al., 2013, Lalitha 
Devi et al., 2009, Patel et al., 2011, Shervington et al., 
2005 and Deekonda et al., 2014 reported various 
analytical methods, like RP-HPLC/UV detection method, 
Spectrofluorimetric method, Capillary Electrophoresis, 
UPLC-MS/MS. Validated stability-indicating RP-HPLC 
methods have been already reported. Fixed dose 
combination of a fluoroquinolone antibiotic (200 mg) and 
an antimicrobial agent CEF (200 mg) would take care of 
both the components of antimicrobial which give greater 
clinical efficacy. The present article introduces a simple, 
specific, precise and rapid RP- HPLC method for 
simultaneous estimation of OFL and CEF in combined 
dosage form.  The developed method is further validated 
and from the validation study, it was found that the 
method is specific, accurate, precise, and reproducible. 
 
 
Figure 1: Chemical structure of (A) OFL and (B) CEF. 
Original Research 
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MATERIALS AND METHODS 
Instrumentation 
The HPLC system consisted of a model LC-20AT 
(Prominence) Shimadzu, Japan was used having UV 
(SPD-20A)Prominence UV/Visible detector. Column  
Phenomenex Gemini C18 –ODS  bonded column of 
length 250 mm and an inter diameter  4.6 mm was 
selected for analysis. The particle size of the stationary 
phase was 5 μ . The Mobile phase was a degassed and 
filtered (0.45 µm, Millipore, Watford, UK)  methanol: 
phosphate buffer (50:50) Flow rate 1 ml/m. Frontline Ultra 
Sonic Cleaner Fs-10 Sonicator was used for sonication 
The column temperature was maintained at 40°C using a 
model 7716 HPLC column block heater CTO-20AC. 
  
Material  
The gift samples of drugs i.e. OFL and CEF was 
provided by Anupam biotech, Manpur, Bhind,  India and 
was confirmed by the official methods. Methanol, 
phosphate buffer and all other chemicals were purchased 
from Himedia labs Mumbai. All the chemicals of HPLC 
and analytical grades and used without any further 
purification. 
 
Standard Solution Preparation 
Methanol: Phosphate buffer (50:50) was used as 
diluent. The stock solutions of   OFL and CEF (1000μg/ml 
of both) were prepared by dissolving an appropriate 
amount of analyte in diluent, separately. Working standard 
solution was prepared in diluent from mixing above stock 
solutions of OFL and CEF with final concentration of 
100μg/ml. 
 
Sample Solution Preparation 
Tablet powder equivalent to 100 mg of OFL and CEF 
was transferred into 100 ml volumetric flask, added 35 ml 
of diluent and ultrasonicated for 20 m, and then diluted to 
volume with diluent. This solution was further diluted with 
diluent to give a solution containing 100 μg/ml of OFL and 
CEF each. 
 
Analysis of Tablet Formulation 
Twenty tablets were weighed accurately, and a 
quantity of tablet powder equivalent to 200 mg OFL and 
200 mg CEF was weighed and aliquate of concentration 
10 g/ml was formed with mobile phase, ultrasonicated 
for 5 m. The solution was filtered through Whatman 
(Florham Park, NJ) No. 41 paper. The tablet sample 
solution was injected, the chromatogram was obtained, 
and the peak areas were recorded. 
 
Validation of the Method  
System Suitability 
System suitability was determined before sample 
analysis from six replicate injections of the standard 
solution containing 10 μg/ml of OFL and CEF each in 
methanol: phosphate buffer (50:50) into the 
chromatograph to determine peak areas, retention times 
(tR) and chromatographic relative standard deviation 
(%RSD). The retention factor (k), theoretical plates (N), 
tailing (Tf) and peak asymmetry (As) chromatographic 
parameters were also evaluated. 
 
Selectivity and Specificity  
The specificity is performed to check ability of method 
to measure the analyte accurately and specifically in 
presence of other components or drugs. The other 
compound should not interfere with drug and should be 
estimated separately. 
 
Linearity, Concentration Range, Limits of Detection 
and Quantitation 
Linearity test solutions were prepared by diluting the 
stock solutions to the required concentrations. The 
solutions were prepared in mobile phase at six 
concentration levels from 5-25 g/ml for OFL and CEF 
both. Calibration curves were plotted between the 
responses of peak versus analyte concentrations. The 
coefficient correlation, slope, y-intercept of the calibration 
curve and % bias at 100% response are reported. For 
LOD and LOQ, 1µg/ml of solution of drugs was prepared 
from standard stock solution of 100 µg/ml by diluting 
appropriate volume with mobile phase. Five standard 
solutions for CEF 0.02, 0.04, 0.06, 0.08 and 0.10 µg/ml 
and for OFL 0.05, 0.06, 0.07, 0.08, 0.09 and 0.10 µg/ml 
were prepared in mobile phase from 1 µg/ml of solution, 
area was noted. The LOD and LOQ of OFL and CEF by 
proposed methods were determined using calibration 
standards. 
 
Precision and Accuracy  
The intra-day precision and accuracy for the proposed 
method were studied at five concentration levels for each 
compound using three replicate determinations for each 
concentration within one day. Similarly, the inter-day 
precision and accuracy were tested by analyzing the 
same three concentrations for each compound using 
three replicate determinations repeated on five days. The 
percentage recoveries for both components were 
calculated using the corresponding regression equations 
and they were satisfactory. The percentage relative 
standard deviation (% RSD) and percentage relative error 
(% Er) did not exceed 2.0% proving the high repeatability 
and accuracy of the developed method % indicating that 
the developed method was accurate for the determination 
of OFL and CEF in pharmaceutical formulation. 
 
Robustness and Ruggedness 
As per ICH guidelines, small, but deliberate variations 
in concentration of the mobile phase were made to check 
the accuracy of the method. These variations did not 
cause any significant difference in the resolution of HPLC 
method. 
 
Analysis of the Pharmaceutical Dosage Form  
The optimized RP-HPLC procedure was applied for 
the assay of this drug combination in the pharmaceutical 
formulation available in the local market (Xiomix–O, Azine 
healthcare Pvt. Ltd.) The active ingredients were 
extracted with the same solvent used for the preparation 
of the standard stock solutions, then dilution was made to 
reach concentration levels within the specified ranges. 
The active ingredients eluted at their specific retention 
times and no interfering peaks were observed from any of 
the inactive ingredients. The photodiode array detection 
enabled peak purity verification where no signs of 
coelution from any of the inactive components were 
detected. Recoveries were calculated using both external 
standard and standard addition methods. The assay 
results of OFL-CEF laboratory-prepared mixtures and 
pharmaceutical preparation revealed satisfactory 
accuracy and precision as indicated from % recovery, SD, 








Stability study and Force degradation  
The purpose of the stability or degradation study was to 
ensure the peak purity of the OFL and CEF in the 
presence of degradation products and establish the 
stability indicating ability of the method. Under basic, 
acidic, peroxide and thermal degradation conditions. 
Studies were performed at 20 μg/ml concentration of OFL 
and CEF on tablets to provide an indication of the 
stability-indicating property and specificity of proposed 
method. By using UV/Visible detector, peak purity test 
was carried out for the OFL and CEF peaks on samples. 
All the solutions were prepared by dissolving the drug 
product in small volume of stressing agents. After 
degradation, these solutions were diluted with diluent to 
yield stated OFL and CEF concentration of about 20 
μg/ml. Conditions employed for performing the stress 
studies were as follows (Samanthula et al., 2013; Roy et 
al., 2013 and Awzalewski et al., 2014) 
 
Base Degradation 
Tablet powder equivalent to 20 mg of OFL and CEF 
was accurately weighed and dissolved in 20 ml of diluent, 
added  5 ml 0.05 N NaOH and the mixture was kept at 
70°C for 1 h. The solution was brought to ambient 
temperature, neutralized by addition of 5 ml 0.1 N HCl and 
diluted to 100 ml with diluent. 5 ml of this solution was 
diluted to 50 ml with diluent. 
 
Acid Degradation 
Tablet powder equivalent to 20 mg of OFL and CEF 
was accurately weighed and dissolved in 20 ml of diluent, 
added 5 ml 0.1 N HCl and the mixture was kept at 70°C 
for 1 h. The solution was brought to ambient temperature, 
neutralized by addition of 5 ml 0.05 N NaOH and diluted 
to 100 ml with diluent. 5 ml of this solution was diluted to 
50 ml with diluent. 
 
Oxidative Degradation 
Tablet powder equivalent to 20 mg of OFL and CEF 
was accurately weighed and dissolved in 20 ml of diluent, 
added 5 ml of 1% hydrogen peroxide. The mixture was 
kept at room temperature for 1 h and diluted to 100 ml 
with diluent. 5 ml of this solution was diluted to 50 ml with 
diluent. 
Hydrolytic Degradation 
Tablet powder equivalent to 20 mg of OFL and CEF 
was accurately weighed and dissolved in 15 ml of diluent, 
added 15 ml of water and the mixture was kept at 70°C 
for 24 h. The solution was brought to ambient temperature 
and diluted to 100 ml with diluent. 5 ml of this solution was 
diluted to 50 ml with diluent. 
 
Thermal Degradation 
Tablet powder equivalent to 20 mg of OFL and CEF 
was stored at 100°C for 12 h, dissolved and diluted to 100 
ml with diluent. 5 ml of this solution was diluted to 50 ml 
with diluent. 
 
RESULTS AND DISCUSSION 
Method Development and Optimization 
The objective of the chromatographic method was to 
separate and quantitate OFL and CEF in presence of 
degradation products. Two component formulations have 
gained a lot of importance as there is greater patient 
acceptability, increased potency and decreased side 
effect.  A calibration curve was plotted for the OFL and 
CEF range of 5-25μg/ml for both to allow an assessment 
of the assay and the plot equation was used for 
quantization. On the optimization of gradient programme, 
OFL and CEF peaks were well resolved form degradation 
products. Based on these experiments, the final optimized 
conditions are described below. Detection wavelength 
was selected by overlain spectra at 276 nm. The injection 
volume was 20 μl. The typical retention time of OFL and 
CEF 4.658 and 2.692 m (Figure 2). The regression value, 
intercept values, determination coefficient (R
2
) and the 
%RSD were evaluated. The limits of detection (LODs) and 
quantitation (LOQs) were determined (n=6) by successive 
dilutions of the lowest calibration plot point. Repeatability 
and intermediate precision for OFL and CEF solutions 
(n=6) were performed in six days and by a single analyst. 
Recovery was determined through the addition of OFL 
and CEF at 50, 75, 100, 125 and 150 % to a tablet 
formulation using methanol: phosphate buffer (50:50). The 
robustness was verified through variation in the mobile 
phase and flow rate for OFL and CEF standard and tablet 
solutions at 10 μg/ml (n=6) (Figure 2). 
 
 
Figure 2: Preliminary chromatograms of OFL and CEF solution prepared in methanol: phosphate buffer (50:50) as the 
mobile phase (1.0 ml/min, C18 –ODS column (250×4.6 mm, 40°C, 20 μL). 
 
Validation of the Method 
Result shows that an excellent correlation existed 
between peak area and concentration of OFL and CEF. 
The linearity range was found to be 5-25 µg/ml for both 
drug and data was shown in Table 1. The LOD values 
were 0.0259 and 0.0206 µg/ml and LOQ values were 
0.0787 and 0.0625 µg/ml for OFL and CEF, respectively 
and shown in table 2. For the determination of accuracy, 
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the sample was spiked with standard and % recovery was 
calculated. The method was found to be accurate and 
precise and data was shown in Table 3. Table 4 shows 
the robustness with respect to change in ratio of mobile 
phase. The assay results of OFL-CEF laboratory-
prepared mixtures and pharmaceutical preparation 
revealed satisfactory accuracy and precision as indicated 
from % recovery, SD, and RSD% values and data was 
shown in Table 5 and 6. It is evident from these results 
that the proposed method is applicable to the assay of this 
drug combination with a satisfactory level of selectivity, 
accuracy, and precision.  
 
Table 1: System suitability parameters 
 
Parameters OFL CEF 
Calibration range (µg/ml) 5-25 5-25 
Retention time (min)                 4.799 1.602 
K 4.09 1.32 
Tf 1.57 1.83 
As 1.18 1.27 
Resolution 4.85 2.73 
Table 2: Evaluation of linearity data, LOD and LOQ 
 
Parameters OFL CEF 
Detection wavelength (nm) 276 276 
Linearity range (µg/ml) 5-25 5-25 
Correlation coefficient 0.99706 0.9970 
Intercept 150577 250577 
Slope 99101 99101 
Detection limit (µg/ml) 0.0259 0.0206 
Quantitation limit (µg/ml) 0.078 0.062 
 
CEF and OFL were found unstable under acidic, basic, 
peroxide, aqeous and thermal condition and degraded 
slightly under thermal degradation. Peak purity test was 
carried out for the OFL and CEF peak by using UV/Visible 
detector in stress samples analysis. CEF was found 
stable but OFL degrades significantly. The purity angle 
was within the purity threshold limit in all of the stressed 
samples, demonstrating the homogeneity of the peaks. A 
summary data of stress study is shown in Table 7 and 
chromatogram shown in Figure 3a-3e. 
 
 






Intra day Inter day 
% Estimated  
± % SDa 
%RSD %Er 
%Estimated 
± % SD 




50 49±0.42 0.86 -2.0 49.3±0.51 1.03 -1.40 
75 76.1±0.90 1.18 1.46 74.2±0.89 1.19 -1.07 
100 100.18±1.63 1.63 0.18 99.1±1.1 1.11 -0.9 
125 125.4±0.81 0.65 0.32 124.2±1.3 1.05 -0.81 




50 49.63±0.43 0.87 0.74 49.7±0.81 1.63 -0.6 
75 76.38±1.16 1.52 1.84 74.1±1.1 1.48 -1.2 
100 100.19±0.24 0.24 0.19 100.1±0.71 0.72 0.1 
125 124.07±0.61 0.49 -0.81 124.3±0.81 0.65 -0.56 
150 149.6±0.42 0.28 -0.27 148.2±0.32 0.22 -1.2 
  
Table 4: Robustness result of HPLC method 
 
Variation in Chromatographic Condition OFL CEF 
 t ±SD a RSD (%) Er (%) t ±SD a RSD (%) Er(%) 
Methanol:phosphate buffer (60:40) 4.498±0.21 0.47 -6.27 1.580±0.03 1.89 -1.37 
Methanol:phosphate buffer (70:30) 4.575±0.01 0.22 -4.66 1.432±0.02 1.39 -10.6 
Methanol:phosphate buffer (40:60) 4.698±0.08 1.70 -2.10 1.421±0.01 0.70 -11.3 
Flow rate 1.5ml/min 4.632±0.10 2.26 -3.47 1.692±0.01 0.59 5.61 
Flow rate 1.1ml/min 4.610±0.03 0.68 -3.93 1.542±0.02 1.29 -3.74 
Flow rate 1.8ml/min 4.532±0.09 2.07 -5.56 1.367±0.03 2.19 -14.7 
 
Table 5: Determination of OFL-CEF laboratory-prepared mixtures using the proposed RP-HPLC method 
 
Nominal value (µg/ml) Found ± SDa (µg/ml) RSD(%) Er (%) 
OFL CEF OFL CEF OFL CEF OFL CEF 
25 25 24.78±0.41 25.08±0.44 1.65 1.75 -0.88 0.32 
25 75 24.89±0.06 74.89±0.36 0.24 0.48 -0.44 -0.15 
50 25 49.34±0.76 24.78±0.25 1.54 1.00 -1.32 -0.88 
50 50 48.87±0.45 49.54±0.38 0.92 0.76 -2.26 -0.92 
75 25 76.02±0.43 24.81±0.31 0.56 1.24 1.36 0.76 
 
Table 6: Analysis of OFL-CEF mixture in its pharmaceutical preparation by the proposed RP-HPLC method 
 
 External standard Standard addition 
 OFL CEF OFL CEF 
% Recovery 100.02 99.87 98 99.26 
±SD 0.41 0.10 0.42 0.81 
%RSD 0.01 0.20 0.86 1.63 
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% Degradation Purity Threshold % Degradation Purity Threshold 
Base hydrolysis 0.05 N NaOH at 70°C, 1 h 10.4 0.257 3.8 0.098 
Acid hydrolysis 0.1 N  HCl at 70°C, 1 h 18.4 0.209 6.5 0.089 
Oxidation 1% H2O2 at RT, 1 h 17.9 0.202 3.3 0.059 
Hydrolytic Water at 70°C, 1 h 5.6 0.212 8.2 0.089 



























































Figure 3: Degradation chromatogram, Alkaline Hydrolytic (3a), Acid Hydrolytic (3b), oxidative (3c), hydrolytic (3d), 
Thermal (3e) of OFL-CEF 
 




A simple and efficient reverse-phase HPLC method 
was developed and validated for quantitative 
determination of OFL and CEF in pharmaceutical dosage 
forms. The method found to be precise, accurate, linear, 
robust and rugged during validation. Satisfactory results 
were obtained from the validation of the method. The 
purity of both analytes was unaffected by the presence of 
degradation products and thus confirms the stability-
indicating power of the developed method. The method is 
stability indicating and can be used for routine analysis of 
production samples.  
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